<DOC>
	<DOCNO>NCT01478542</DOCNO>
	<brief_summary>The purpose study improve outcome elderly patient CD20+ Aggressive B-Cell Lymphoma reduce toxicity standard use Immuno-Chemotherapy use optimised schedule monoclonal antibody Rituximab , substitute conventional Liposomal Vincristine PET-guided reduction therapy Combination Vitamin D Substitution .</brief_summary>
	<brief_title>OPTIMAL &gt; 60 / DR. CHOP , Improvement Therapy Elderly Patients With CD20+ DLBCL Using Rituximab Optimized Liposomal Vincristine</brief_title>
	<detailed_description>Primary objective study : `` OPTIMAL &gt; 60 Less Favourable '' Patients less favourable prognosis : To test whether progression-free survival ( PFS ) improve substituting conventional liposomal vincristine ; To test whether PFS improve 12 optimised application instead 8 2-week application rituximab . `` OPTIMAL &gt; 60 Favourable '' : Patients favourable pro-gnosis : Comparison neurotoxicity conventional liposomal vincristine ; Determination PFS treatment strategy reduce treatment patient negative FDG-PET 4 x R-CHOP/CHLIP-14 ( PET-4 ) comparison correspond patient population RICOVER-60 . Secondary objective : `` OPTIMAL &gt; 60 Favourable '' `` OPTIMAL &gt; 60 Less Favourable '' : Comparison prognostic value pre-treatment FDG-PET ( PET-0 ) conventional CT/MRT . Investigation prognostic value different FDG-PET derive image biomarkers lymphoma load ( SUV , MTV , TLG ) . Comparison FDG-PET-based individualised treatment strategy OPTIMAL &gt; 60 fix ( pre-defined ) treatment strategy RICOVER &gt; 60 . Estimation vincristine-related neurotoxicity ( `` OPTIMAL &gt; 60 Less Favourable , since vincristine relate neurotoxicity primary objective study favourable patient ) toxicity ( patient ) . Determination therapeutic efficacy Vitamin D substitution compare first patient without Vitamin D substitution patient Vitamin D substitution .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Age : 6180 year 2 . All risk group ( IPI 15 ) 3 . Diagnosis aggressive CD20+ BNHL , base excisional biopsy lymph node appropriate sample lymph node extranodal involvement . It possible treat follow entity study define new WHO classification 200870 : BNHL : Foll . lymphoma grade IIIb DLBCL , otherwise specify ( NOS ) common morphologic variant : centroblastic immunoblastic anaplastic rare morphologic variant DLBCL subtypes/entities : Tcell/histiocyterich large Bcell lymphoma primary cutaneous DLBCL , leg type EBVpos . DLBCL elderly DLBCL associate chronic inflammation primary mediastinal ( thymic ) LBCL intravascular large Bcelllymphoma ALKpositive large Bcelllymphoma plasmoblastic lymphoma primary effusion lymphoma transform indolent lymphoma secondary simultaneous high grade Bcelllymphoma Bcell lymphoma , unclassifiable , feature intermediate DLBCL Burkitt lymphoma Bcell lymphoma , unclassifiable , feature intermediate DLCBL Hodgkin lymphoma 4 . Performance status ECOG 0 2 prephase treatment . The performance status patient must assess initiation end prephase treatment , experience show , result significant improvement patient 's performance status . The pretreatment performance status range ECOG 0 ECOG 4 must document Staging CRF ( see ISF ) ; performance status prephase treatment must document respective Prephase Treatment CRF ( PT form : see ISF ) . A definition performance status provide Appendix 28.10 . 5 . Written informed consent patient 6 . Contract participation sign study centre sponsor 1 . Already initiated lymphoma therapy ( except prephase treatment ) 2 . Serious accompany disorder impair organ function ( except due lymphoma involvement ) , particular : heart : angina pectoris CCS &gt; 2 , cardiac failure e.g . NYHA &gt; 2 and/or EF &lt; 50 % FS &lt; 25 % nuclear medicine examination/echocardiography lung : respiratory problem suspect patient exclude resultant pulmonary function test show FeV1 &lt; 50 % diffusion capacity &lt; 50 % reference value kidney : creatinine &gt; 2 time upper reference limit liver : bilirubin &gt; 2 time upper reference limit , aspartate transaminase ( AST , SGOT ) alanine transaminase ( ALT , SGPT ) &gt; 3 x institutional upper reference limit uncontrollable diabetes mellitus ( prephase treatment predniso [ lo ] ne ! ) 3 . Platelets &lt; 75 000/mm3 , leukocytes &lt; 2 500/mm3 ( due lymphoma ) 4 . Known hypersensitivity medication use 5 . Known HIVpositivity 6 . Patients severe impairment immune defense 7 . Patients constipation imminent risk ileus 8 . Chronic active hepatitis 9 . Poor patient compliance 10 . Simultaneous participation treatment study another clinical trial within last 6 month 11 . Prior chemo radiotherapy , longterm use corticosteroid antineoplastic drug previous disorder 12 . Other concomitant tumour disease and/or tumour disease past 5 year ( except localise skin tumor melanoma carcinomas situ origin ) 13 . CNS involvement lymphoma ( intracerebral , meningeal , intraspinal intradural ) primary CNS lymphoma 14 . Persistent neuropathy grade â‰¥2 ( NCI CTCAE v4.03 ) ( unless due lymphoma involvement ) 15 . History persistent active neurologic disorder grade &gt; 2 include demyelinate form CharcotMarieTooth syndrome , acquire demyelinate disorder , demyelinate condition 16 . Pregnancy breastfeed woman 17 . Active serious infection control oral and/or intravenous antibiotic antifungal medication 18 . Any medical condition opinion investigator place subject unacceptably high risk toxicity . 19 . MALT lymphoma 20 . Nonconformity eligibility criterion 21 . Persons able understand impact , nature , risk consequence trial ( include language barrier ) 22 . Persons agree transmission pseudonymous data 23 . Persons depend sponsor investigator 24 . Persons highly protect group . Pts . CNS lymphoma include study .</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Liposomal Vincristine ( Marqibo )</keyword>
	<keyword>Optimised Rituximab</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Elderly Patients</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>Bulky Disease</keyword>
	<keyword>Radiation</keyword>
	<keyword>age &gt; 60 year</keyword>
	<keyword>First line Therapy</keyword>
	<keyword>Vitamin D</keyword>
</DOC>